Join to View Full Profile
55 Fruit St# 7EBoston, MA 02114
Phone+1 617-724-4000
Fax+1 617-726-8685
Dr. Saylor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Philip Saylor is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 14 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in amyloidosis, hematologic oncology, prostate cancer, myelodysplasia, and myelofibrosis.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
University of California (San Diego) Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Pittsburgh School of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2005 - 2027
MA State Medical License 2008 - 2027
ME State Medical License 2020 - 2027
NH State Medical License 2021 - 2027
RI State Medical License 2021 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis.Zsombor T Gal, Ethan A Wetzel, Brian V Nahed, Philip J Saylor, Joshua A Hirsch
The Spine Journal. 2026-04-01 - Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer.Alexander Herold, Maximilian Pohl, Stephan M Korn, Michael Weber, Jason A Efstathiou
Abdominal Radiology. 2026-04-01 - 1 citationsAndrogen receptor splice variant expression and prostate cancer recurrence after salvage therapy.David J Konieczkowski, Keisuke Otani, Zoe Guan, Michael R Drumm, Yukako Otani
NPJ Precision Oncology. 2025-12-01
Press Mentions
Outside the Guidelines: Denosumab Overuse in Prostate CancerMarch 4th, 2024- SUO 2023: Bone Support Throughout the Prostate Cancer JourneyNovember 30th, 2023
- Outside the Guidelines: Denosumab Overuse in Prostate CancerMarch 7th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
